Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 11039

Another biomarker of senescent cells could be p16, a protein whose levels increase when cells stop dividing if old and also a protein whose gene is turned off in many human cancers.

Coming back to our topic – designing senolytics that avoid the apoptosis of young, healthy cells – the ideal senolytic should accomplish two things: –turn on p53 at increased levels to determine stubborn, senescent cells to commit suicide –do that on senescent cells only.

And in order to accomplish the second part, such a drug should be ‘programmed’ to only act on those cells where it recognizes senescence-associated biomarkers. There is no single biomarker today that stains positive or negative on all types of senescence cells, but increased levels of beta-galactosidase and p16 proteins could be a welcome start to identify old cells in vivo when designing such a drug.

Read more

Since the beginning of the Space Age, scientists have relied on multi-stage rockets in order to put spacecraft and payloads into orbit. The same technology has allowed for missions farther into space, sending robotic spacecraft to every planet in the Solar System, and astronauts to the Moon. But looking to the future, it is clear that new ideas will be needed in order to cut costs and expand launch services.

Hence why the ARCA Space Corporation has developed a concept for a single-stage-to-orbit (SSTO) rocket. It’s known as the Haas 2CA, the latest in a series of rockets being developed by the New Mexico-based aerospace company. If all goes as planned, this rocket will be the first SSTO rocket in history, meaning it will be able to place payloads and crew into Earth’s orbit relying on only one stage with one engine.

The rocket was unveiled on Tuesday, March 28th, at their company headquarters in Las Cruces. The rocket is currently seeking FAA approval, and ARCA is working diligently to get it ready for its test launch in 2018 – which will take place at NASA’s Wallops Flight Facility located on Virginia’s eastern shore. If successful, the company hopes to use this rocket to deploy small satellites to orbit in the coming decade.

Read more

Genomic instability (mutations) has been suggested as being one of the primary hallmarks of aging and this research might support that idea. Researchers at John Hopkins report that around 66% of mutations in cancer cells are due to random errors with environment/lifestyle contributing 29% and 5% inherited.

“That finding challenges the common wisdom that cancer is the product of heredity and the environment. “There’s a third cause and this cause of mutations is a major cause,” says cancer geneticist Bert Vogelstein.”

“Such random mutations build up over time and help explain why cancer strikes older people more often. Knowing that the enemy will strike from within even when people protect themselves against external threats indicates that early cancer detection and treatment deserve greater attention than they have previously gotten, Vogelstein says.”

Read more

The team tested their device on a prosthetic hand. When the skin patches on the skin were enabled, the prosthetic could touch and grab soft objects like a normal hand. But when the skin was not turned on, the hand crushed the objects.

The skin requires just 20 nanowatts of power per square centimeter, according to the paper. Right now, the energy captured by the photovoltaic cells has to be used immediately, but the team has another prototype in development that includes flexible supercapacitors to store excess energy.

They are also working on scaling up the material to cover larger areas of a prosthetic or robot, using a method the team pioneered in 2015 for inexpensively producing large sheets of graphene. Dahiya expects the skin will eventually be produced for just $1 for 5 to 10 centimeters of the material.

Read more

Fasting might help T1 diabetics according to new research.

Periodic fasting has long been demonstrated to have beneficial effects on autoimmune disorders, cancer prevention and treatments, cardiovascular disease and a myriad of other ailments. This most recent paper by Cheng et al. may add the treatment of Type 1 diabetes to that list[1]. If successful in humans it has the potential to reverse some or most of the loss of insulin producing cells within the pancreas. Just as remarkable, the treatment itself is relatively straightforward, consisting of a regimented protocol of periodic fasting-like conditions.

Generally speaking, Type 1 diabetes results from an autoimmune mediated depletion of insulin secreting pancreatic beta islet cells. In contrast, Type 2 results from lower cellular sensitivity to insulin. Type 2 is primarily caused by environmental factors such as poor diet.

The current medical approach to treating Type 1 diabetes is the periodic administration of insulin, usually through self-administered injections. Most new therapies focused on curing Type 1 diabetes are looking to repopulating beta islet cells through the use of reprogrammed induced pluripotent stem (iPS) cells.

Continue reading “Research Suggests Periodic Fasting Might Reverse Type 1 Diabetes” | >

Tencent, Asia’s second highest valued tech firm, has bought a five percent share in Tesla. According to a filing, the Chinese firm scooped up 8,167,for around $1.7 billion to become one of Tesla’s largest shareholders.

The news itself sent Tesla’s share price up three percent in pre-market trading. The purchase was arranged on March 17, and those now-Tencent-owned shares are worth around $2.2 billion at current market value.

Tencent is a prolific investor. It holds equity in Snap, this year’s hot tech IPO, among others following an early investment. While that interest in messaging makes sense since Tencent’s operates China’s dominant chat app — WeChat — it isn’t immediately clear whether the Tesla investment has strategic undertones. An alliance with Tencent could significantly boost Tesla’s efforts in China, which is already impressive. Chinese sales accounted for 15 percent of Tesla’s $7 billion revenue last year.

Read more